Kezar Life Sciences Inc (KZR)
NASDAQ:KZR
Top Page
Kezar Life Sciences
(NASDAQ:KZR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$6.50
▲(5.01% Upside)
Action:ReiteratedDate:12/30/25
The score is held down primarily by weak financial performance (no recent revenue, persistent large losses, and heavy cash burn), with additional pressure from negative corporate developments around regulatory setbacks and restructuring. These risks are partly balanced by improving technical momentum and a low-leverage balance sheet, while valuation support is limited given ongoing losses and no dividend.
Positive Factors
Business Model Strength
Kezar's focus on novel therapies for unmet needs in autoimmune diseases and cancer positions it well in the biotech industry, potentially leading to significant breakthroughs and market opportunities.
Negative Factors
Revenue Generation Challenges
The lack of revenue generation highlights challenges in commercializing products, which could hinder financial sustainability and growth prospects if not addressed.
Read all positive and negative factors
Positive Factors
Negative Factors
Business Model Strength
Kezar's focus on novel therapies for unmet needs in autoimmune diseases and cancer positions it well in the biotech industry, potentially leading to significant breakthroughs and market opportunities.
Read all positive factors
Kezar Life Sciences (KZR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$46.94M
Dividend YieldN/A
Average Volume (3M)297.79K
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue GrowthN/A
EPS Growth35.80%
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding7,323,156
10 Day Avg. Volume813,550
30 Day Avg. Volume297,789
Financial Highlights & Ratios
PEG Ratio0.33
Price to Book (P/B)4.19
Price to Sales (P/S)0.00
P/FCF Ratio-6.60
Enterprise Value/Market Cap0.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.49
Enterprise Value/Ebitda-0.30
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.74
Revenue Forecast (FY)N/A
Kezar Life Sciences Business Overview & Revenue Model
Company Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead p...
How the Company Makes Money
Kezar Life Sciences generates revenue primarily through strategic partnerships, collaborations, and potential licensing agreements with other pharmaceutical and biotechnology companies. These partnerships may include upfront payments, milestone pa...
Kezar Life Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
56
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 7.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -478.00K | -1.04M | 7.00M | 0.00 | -1.51M | -1.54M |
| EBITDA | -59.69M | -81.10M | -99.25M | -66.03M | -52.96M | -40.26M |
| Net Income | -61.70M | -83.74M | -101.87M | -68.24M | -54.63M | -41.74M |
Balance Sheet | ||||||
| Total Assets | 97.73M | 144.68M | 221.24M | 299.57M | 217.93M | 151.84M |
| Cash, Cash Equivalents and Short-Term Investments | 90.22M | 132.25M | 201.37M | 276.56M | 208.35M | 140.45M |
| Total Debt | 9.91M | 16.18M | 18.93M | 21.26M | 14.04M | 5.46M |
| Total Liabilities | 14.75M | 27.77M | 33.66M | 29.70M | 21.06M | 10.86M |
| Stockholders Equity | 82.98M | 116.92M | 187.57M | 269.87M | 196.88M | 140.98M |
Cash Flow | ||||||
| Free Cash Flow | -56.66M | -74.24M | -83.45M | -60.42M | -42.75M | -37.14M |
| Operating Cash Flow | -56.64M | -74.21M | -81.64M | -58.85M | -42.44M | -36.95M |
| Investing Cash Flow | 64.59M | 80.43M | 76.05M | -91.39M | -28.44M | -56.50M |
| Financing Cash Flow | -3.83M | 103.00K | 638.00K | 127.86M | 112.58M | 99.64M |
Kezar Life Sciences Technical Analysis
Neutral
6.19
Price Trends
6.50
Negative
6.37
Positive
5.34
Positive
Market Momentum
0.02
Positive
40.48
Neutral
10.16
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KZR, the sentiment is Neutral. The current price of 6.19 is below the 20-day moving average (MA) of 6.87, below the 50-day MA of 6.50, and above the 200-day MA of 5.34, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 40.48 is Neutral, neither overbought nor oversold. The STOCH value of 10.16 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KZR.
Kezar Life Sciences Risk Analysis
Kezar Life Sciences disclosed 63 risk factors in its most recent earnings report. Kezar Life Sciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kezar Life Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $79.20M | -2.64 | -291.42% | ― | ― | 61.23% | |
52 Neutral | $46.94M | -0.64 | -62.53% | ― | ― | 35.80% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $27.98M | -2.65 | -108.76% | ― | -100.00% | 33.44% | |
42 Neutral | $4.73M | ― | -68.21% | ― | ― | ― |
* Healthcare Sector Average
KZR
Kezar Life Sciences
6.41
0.77
13.65%
AKTX
Akari Therapeutics
0.14
-1.32
-90.62%
XCUR
Exicure
4.47
-8.80
-66.31%
PYPD
PolyPid
4.08
1.28
45.71%
Kezar Life Sciences Corporate Events
Business Operations and Strategy
Kezar Life Sciences Announces Major Workforce Reduction
Negative
Nov 7, 2025
On November 6, 2025, Kezar Life Sciences announced a restructuring plan that involves reducing its workforce by approximately 70%, equating to about 31 employees. This decision is part of the company’s strategic evaluation of alternatives an...
Business Operations and StrategyPrivate Placements and Financing
Kezar Life Sciences Repays Loan, Ends Agreement
Positive
Oct 22, 2025
On October 20, 2025, Kezar Life Sciences, Inc. fully repaid $6.3 million under its Loan and Security Agreement with Oxford Finance LLC, effectively terminating the agreement and releasing all associated liens and security interests. This financial...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Kezar Life Sciences Faces FDA Challenges in Drug Program
Negative
Oct 16, 2025
On October 16, 2025, Kezar Life Sciences announced a regulatory update regarding its zetomipzomib program for autoimmune hepatitis, revealing challenges in aligning with the FDA on a clinical trial. The FDA’s request for additional studies c...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.